Kanvas Biosciences

Kanvas Biosciences is a private, preclinical-stage biotech leveraging a proprietary spatial mapping technology to illuminate the microbiome and develop next-generation live biotherapeutics. Its vertically integrated platform, spanning from discovery via HiPR-FISH imaging to scalable anaerobic co-culture manufacturing (ACT™), aims to accelerate the development of microbial consortia for diseases like cancer. The company has established a key partnership with MD Anderson Cancer Center and is advancing its lead program, KAN-001, for checkpoint inhibitor-refractory and naïve cancers. Backed by venture capital, including a recent $12.5 million raise, Kanvas is positioning itself at the intersection of advanced imaging, microbiome science, and immuno-oncology.

Vertically integrated platform for live biotherapeutic discovery and manufacturing. Core technology is HiPR-FISH, a high-resolution spatial imaging platform that maps host-microbiome interactions in situ. Integrated with proprietary Anaerobic Co-culture Technology (ACT™) for scalable, reproducible manufacturing of microbial consortia.

Kanvas competes in the live biotherapeutic product space with companies like Seres Therapeutics, Vedanta Biosciences, and MaaT Pharma, all of which have advanced clinical programs. Its key differentiation is the HiPR-FISH spatial imaging platform for discovery and its vertically integrated model, which includes proprietary manufacturing. Larger pharma companies (e.g., Merck, Bristol Myers Squibb) are also active in the space through partnerships and internal research.